
Dianthus marks Nasdaq debut with PhI hit; Arbutus shuts oral RNA and coronavirus programs
As Dianthus Therapeutics starts trading on Nasdaq, it’s also marking another milestone with positive Phase I safety and pharmacokinetic data.
DNTH103, a selective inhibitor of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.